NUVB logo

Nuvation Bio Inc. Stock Price

NYSE:NUVB Community·US$2.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 41 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

NUVB Share Price Performance

US$6.28
2.93 (87.46%)
​
US$13.11
Fair Value
US$6.28
2.93 (87.46%)
52.1% undervalued intrinsic discount
US$13.11
Fair Value
Price US$6.28
AnalystConsensusTarget US$13.11
AnalystHighTarget US$21.00
AnalystLowTarget US$7.00

NUVB Community Narratives

Fair Value
·
Fair Value US$13.11 52.1% undervalued intrinsic discount

Emerging Glioma Therapy And Lung Cancer Expansion Will Transform Long Term Oncology Franchise

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Fair Value
·
Fair Value US$21 70.1% undervalued intrinsic discount

ROS1 Lung Cancer Leadership And Glioma Opportunity Will Transform Long Term Oncology Impact

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Fair Value
·
Fair Value US$7 10.3% undervalued intrinsic discount

RNA Testing And Glioma Program Will Shape Long Term Prospects Despite Near Term Uncertainty

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
NUVB logo
Nuvation Bio
70.1% undervalued intrinsic discount

ROS1 Lung Cancer Leadership And Glioma Opportunity Will Transform Long Term Oncology Impact

View narrative
Updated 27 Aug
Read Narrative
NUVB logo
Nuvation Bio
52.1% undervalued intrinsic discount

Emerging Glioma Therapy And Lung Cancer Expansion Will Transform Long Term Oncology Franchise

View narrative
Updated 13 Aug
Read Narrative
NUVB logo
Nuvation Bio
10.3% undervalued intrinsic discount

RNA Testing And Glioma Program Will Shape Long Term Prospects Despite Near Term Uncertainty

View narrative
Updated 24 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Updated Narratives

NUVB logo

NUVB: Fast Track Glioma Program Will Drive Future Oncology Portfolio Upside

Fair Value: US$21 70.1% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NUVB logo

NUVB: Safusidenib Glioma Data Will Drive Future Upside Potential

Fair Value: US$13.11 52.1% undervalued intrinsic discount
6 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NUVB logo

NUVB: Glioma Data And Lung Cancer Progress Will Shape Future Upside And Risks

Fair Value: US$7 10.3% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

High growth potential with adequate balance sheet.

0 Risks
2 Rewards
View Full Analysis

Nuvation Bio Inc. Key Details

US$169.9m

Revenue

US$20.1m

Cost of Revenue

US$149.8m

Gross Profit

US$299.6m

Other Expenses

-US$149.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.43
88.18%
-88.19%
162.5%
View Full Analysis

About NUVB

Founded
2018
Employees
305
CEO
David Hung
WebsiteView website
www.nuvationbio.com

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Recent NUVB News & Updates

Narrative Update • Aug 27

NUVB: Fast Track Glioma Program Will Drive Future Oncology Portfolio Upside

Analysts lifted their average price target on Nuvation Bio to $21.00, supported by fresh coverage that highlights perceived undervaluation, growing confidence in Ibtrozi and safusidenib, and updated assumptions around margins and future P/E. Analyst Commentary Recent research coverage on Nuvation Bio points to a cluster of positive views around the commercial ramp of Ibtrozi and the potential of safusidenib.
Seeking Alpha • Aug 26

Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts

Summary Nuvation Bio Inc. is downgraded to Hold after a >200% share price run, reflecting cautious optimism amid early Ibtrozi launch dynamics. Ibtrozi, now the leading ROS1 TKI in new patient starts, posted $23.2m Q2 revenues with strong first-line uptake, but overall patient starts declined sequentially. NUVB management projects a $3.8bn Ibtrozi peak revenue opportunity, but current sales and analyst estimates suggest a more modest trajectory near $650m. Safusidenib offers promising pipeline potential in IDH1-mutant glioma yet faces entrenched competition and a lengthy path to approval. Read the full article on Seeking Alpha

Recent updates

No updates

Nuvation Bio Inc. Competitors

SMMT logo

Summit Therapeutics

Symbol: NasdaqGM:SMMT
Market cap: US$13.6b
CRL logo

Charles River Laboratories International

Symbol: NYSE:CRL
Market cap: US$13.3b
MDGL logo

Madrigal Pharmaceuticals

Symbol: NasdaqGS:MDGL
Market cap: US$12.6b
CORT logo

Corcept Therapeutics

Symbol: NasdaqCM:CORT
Market cap: US$12.5b
View more competitors